News Category
Tonix Pharmaceuticals will present at Guggenheim's 3rd Annual Healthcare Innovation Conference on Nov. 10, 2026, providing investors an update on its ...
Quantum BioPharma advances a broad strategy combining drug development, consumer wellness, and royalty partnerships to address the massive unmet need ...
Quantum BioPharma's unbuzzd supplement, designed to support alcohol metabolism, has been highlighted by Men's Fitness after a small placebo-controlled...
Quantum BioPharma's unbuzzd supplement drink, designed to support alcohol metabolism, has drawn attention from Men's Fitness after a clinical trial sh...
Okogen has dosed the first patient in its Phase 1/2 EMERALD Trial of Treyegen, a potential single therapy for acute infectious conjunctivitis, marking...
Preliminary research presented at the American Heart Association's Scientific Sessions 2026 found that non-specialists using AI guidance in mobile uni...
New preliminary research shows out-of-hospital cardiac arrest ICU admissions jump by up to 102% on days reaching 98°F, with women and older adults at ...
Catherine Cifuentes-Rojas, a biotherapeutics veteran now at Ginkgo Bioworks, has released a free five-question go/no-go checklist to help discovery te...
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher Scientific's clinical research business to advance its Phase 2 trial of Luc...
Annovis Bio CEO Maria Maccecchini will present at two November biotechnology conferences, highlighting the company's clinical programs for Alzheimer's...
NanoViricides reports progress in its Phase IIA trial of NV-387 Oral Gummies for Ebola Bundibugyo virus disease in the DRC, where over 10,000 cases an...
A mutated flu version is driving an earlier-than-expected outbreak on the West Coast, prompting experts to call for urgent vaccination drives and high...
Tonix Pharmaceuticals presented Phase 3 data at the IASP 2026 World Congress showing its newly approved fibromyalgia drug TONMYA significantly improve...
Tonix Pharmaceuticals will report third-quarter 2026 financial results and operational highlights on Nov. 9, giving investors a scheduled update on a ...
Annovis Bio will present three buntanetap studies at the 2026 CTAD conference, highlighting its Phase 3 Alzheimer's program ahead of a pivotal data re...
NeuroThera Labs has completed manufacturing and received European Qualified Person batch release for its investigational drug SCI-110, enabling shipme...
BioVersys announced peer-reviewed publications showing its antibiotic BV100 achieves high lung concentrations and has a milder drug-interaction profil...
A Men's Fitness examination of Quantum BioPharma's Unbuzzd alcohol recovery formulation highlights promising but preliminary trial results, underscori...
NanoViricides reported positive juvenile animal safety results for its broad-spectrum antiviral NV-387, potentially enabling pediatric trials for Ebol...
Quantum BioPharma's Unbuzzd formulation demonstrated significant reductions in blood alcohol concentration and improved alertness in a small clinical ...
Tonix Pharmaceuticals will present new data on its recently approved fibromyalgia treatment TONMYA at the 2026 IASP World Congress on Pain, highlighti...
Health experts warn that measles infections cause long-term immune vulnerabilities, urging increased vaccination and decentralized testing to prevent ...
Tonix Pharmaceuticals will present its investigational TNX-801 vaccine platform for mpox at the World Vaccine Congress Europe, highlighting its potent...
OrthodontiCell has secured sufficient capital to complete the remaining testing needed to support its application for a planned Phase II pivotal clini...
hyperCORE International has elected Jeffrey Smyth as President, Seneca Harrison as Vice President, and Claxton Copeland as Secretary, with Dustin Owen...
Quantum BioPharma has received FDA approval to begin Phase 2 clinical testing of Lucid-MS, a potential first-in-class multiple sclerosis therapy that ...
The American Heart Association has selected five health technology companies as finalists for its 2026 Health Tech Competition, aiming to accelerate i...
NanoViricides reports progress in its Phase IIA trial of NV-387 Oral Gummies for Ebola Bundibugyo virus, potentially leading to a Phase IIB study and ...
Nutriband Inc. has raised approximately $1.75 million through warrant exercises, funds it will use to support clinical development and a New Drug Appl...
Leksum LLC has signed an agreement with the Medical University of Vienna to prepare for first-in-human clinical trials of LK-ICU, a therapy that may p...
The American Heart Association has launched a comprehensive education portfolio to help clinicians apply the new cardiovascular-kidney-metabolic (CKM)...
Newron Pharmaceuticals has received FDA feedback on a clinical hold at U.S. sites for its Phase 3 ENIGMA-TRS 2 trial of evenamide, but remains confide...
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher Scientific's clinical research business to implement the Phase 2 trial of L...
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher's clinical research business to launch a Phase 2 trial of Lucid-MS, a new m...
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher Scientific's clinical research business to initiate a Phase 2 trial of Luci...
XORTX Therapeutics is advancing its gout treatment XORLO toward a New Drug Application with the FDA, aiming to address the limitations of current ther...
Quantum BioPharma has entered a Study Start-Up Agreement with Thermo Fisher Scientific to initiate Phase 2 trial activities for Lucid-MS, a potential ...
NanoViricides will present at the NIBA 153rd Investment Conference on Oct. 7, 2026, highlighting its broad-spectrum antiviral NV-387, which is in Phas...
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher Scientific to implement its Phase 2 trial of Lucid-MS for multiple sclerosi...
Okogen's Treyegen (OKG-0303) has received CDSCO authorization to begin a Phase 1/2 trial in India, potentially offering the first single therapy for b...
NanoViricides is progressing its Phase II clinical trial of NV-387 Oral Gummies for Bundibugyo Ebolavirus in the Democratic Republic of Congo, with en...
Nutriband Inc. celebrates five years on Nasdaq with key milestones in its abuse-deterrent fentanyl patch and outlines upcoming regulatory steps.
Gianluca Cerri, MD, is promoting a personal policy that emergency physicians should discuss medication-assisted treatment with opioid use disorder pat...
Stonegate Capital Partners' updated coverage highlights Incannex Healthcare's progress with IHL-42X, which has moved into active clinical execution wi...
A new novel by AAG Zacheriel explores the consequences of compromised clinical trial data, raising timely questions about trust in medical research an...
Quantum BioPharma is advancing its multiple sclerosis drug candidate Lucid-MS into Phase 2 trials while also holding a stake and royalty stream in the...
Quantum BioPharma is advancing its Lucid-MS drug candidate to a Phase 2 trial in multiple sclerosis patients and is highlighting the commercial potent...
A new NFID survey shows 77% of U.S. adults support vaccines, but only 48% got a respiratory vaccine in the past year, highlighting gaps in awareness a...
